Sarcopenia and peripheral arterial disease: a systematic review.
Mégane PizzimentiAlain MeyerAnne-Laure CharlesMargherita GianniniNabil ChakféAnne LejayBernard GenyPublished in: Journal of cachexia, sarcopenia and muscle (2020)
Sarcopenia and lower extremity PAD have musculoskeletal consequences that directly impair patients' quality of life and prognosis. Although PAD is primarily a vascular disease, all etiological factors of sarcopenia identified so far are present in PAD. Indeed, both sarcopenia and PAD are accompanied by oxidative stress, skeletal muscle mitochondrial impairments, inflammation, inhibition of specific pathways regulating muscle synthesis or protection (i.e. IGF-1, RISK, and SAFE), and activation of molecules associated with muscle degradation. To date, besides revascularization, the best therapeutic strategy includes exercise, but approaches targeting the underlying mechanisms still deserve further studies.
Keyphrases
- skeletal muscle
- oxidative stress
- insulin resistance
- end stage renal disease
- ejection fraction
- newly diagnosed
- ischemia reperfusion injury
- physical activity
- dna damage
- diabetic rats
- percutaneous coronary intervention
- high intensity
- cancer therapy
- patient reported outcomes
- induced apoptosis
- cell proliferation
- coronary artery disease
- atrial fibrillation
- drug delivery
- binding protein
- growth hormone